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Background: For detecting tumor recurrence of medullary thyroid carcinoma (MTC) 
in the neck, an appropriate frequency and interval of postoperative ultrasonography 
(US) surveillance remains unclear. This study aimed to assess an appropriate interval 
and frequency of postoperative neck US surveillance for detecting tumor recurrence in 
patients who had undergone thyroid surgery due to MTC.
Methods: A total of 86 patients who had undergone thyroid surgery for the treatment of 
MTC and had at least one postoperative US follow-up examination at any of nine affili-
ated hospitals were included. Postoperative follow-up US, clinical, and histopathological 
results of patients were reviewed. The tumor recurrence/persistence rate of MTC was 
investigated, and the interval and session number of postoperative follow-up US and 
clinicopathologic factors were compared between tumor recurrence/persistence and 
non-recurrence groups.
results: Of the 86 patients, 22 (25.6%) showed tumor recurrence/persistence. Of the 
22 patients with tumor recurrence/persistence, 11 (50%) showed structural recurrence/
persistence in the neck on follow-up US. In these 11 patients, the mean interval and 
session number of postoperative follow-up US between initial surgery and the first US 
detection of recurrence/persistence was 41.3 ± 39.3 months (range, 6–128 months) and 
2.6 ± 2.3 (range, 1–8), respectively. On follow-up US, 6 (54.5%, 6/11) were diagnosed 
with tumor recurrence/persistence within 3 years of the initial surgery. Tumor recurrence/
persistence was significantly correlated with TNM stage (p <  0.001) and multiplicity/
bilaterality (p = 0.013).
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conclusion: For detecting MTC recurrence/persistence, postoperative US surveillance 
at 1-year intervals may be sufficient within the first 3  years after thyroid surgery, but 
depending on the presence of relevant risk factors, annual or biannual US surveillance 
may be recommendable for 4–10 years after thyroid surgery.
Keywords: thyroid, malignancy, medullary thyroid carcinoma, ultrasonography, recurrence, surveillance
inTrODUcTiOn
Medullary thyroid carcinoma (MTC) is an uncommon thyroid 
cancer which accounts for 3–10% of all thyroid cancers (1, 2). 
MTCs are derived from the parafollicular C-cells that produce 
calcitonin, and serum calcitonin level is known to be a sensitive 
and specific marker for MTC (3). However, several reports sug-
gest that advanced MTC may dedifferentiate with a subsequent 
decrease in calcitonin production (4, 5).
The prognosis of MTC is intermediate between differentiated 
and anaplastic thyroid carcinomas (1). The natural course of 
MTC varies from very slow progression or stable disease extend-
ing over decades to rapid progression and survival of just a few 
years (1). The reported 5-year survival of MTC is 78–91%, and 
the reported 10-year survival is 61–88% (1, 6). Distant metastasis, 
which is reportedly observed at initial presentation in 7–23% of 
patients, is known to be the main cause of MTC-related mortality 
(7). Distant metastasis, older age at diagnosis, and more advanced 
primary tumor or nodal stage have been proposed as prognostic 
factors for adverse outcomes (8, 9). Also, serum kinetics of MTC 
markers, such as calcitonin and carcinoembryonic antigen, may 
be alternative predictors of survival (10).
Thyroid ultrasonography (US) has been used to differenti-
ate between malignant and benign thyroid nodules, to guide 
fine-needle aspiration of suspicious thyroid nodules, and to 
detect tumor recurrence after thyroid surgery (11, 12). Due to 
an increase in thyroid US screening, the detection rate of small 
thyroid cancers has increased substantially, and earlier detection 
of smaller MTCs is possible (13–15). In particular, Elisei et al. 
reported US follow-up results including the neck in patients who 
had undergone thyroid surgery due to MTC (16). They recom-
mended that postoperative neck US be undertaken at interval of 
6–12 months. However, this may be too short interval, and can 
result in unnecessary medical costs. To the best of our knowl-
edge, an appropriate interval for postoperative US surveillance 
remains unclear. This study aimed to determine the detection 
rate of tumor recurrence/persistence and characteristics of post-
operative follow-up US in MTC patients by analyzing follow-up 




This retrospective analysis was based on patient data collected 
from nine university-affiliated hospitals. The institutional review 
boards of all participating institutions approved the study, and the 
need for informed consent was waived due to the retrospective 
nature of the study. From January 2005 to April 2011, only 
patients who met the following criteria were consecutively 
included, although the start time for patient selection differed 
among the institutions due to the scarcity and variations in the 
number of MTC cases at each institution: (1) patients who had 
undergone thyroid surgery for the treatment of MTC, (2) patients 
who had at least one postoperative US follow-up examination 
during the follow-up period, (3) patients who had been clinical 
followed-up for more than 5 years after the initial thyroid surgery, 
and (4) patients in which the presence or absence of tumor recur-
rence/persistence could be determined. Ultimately, a total of 86 
patients (53 women and 33 men, age range 7–76 years, mean age 
53.1 ± 11.8 years) were included in the study.
neck Us examinations and Follow-ups
All US examinations were performed using one of the following 
high-resolution US systems: (1) iU 22 (Philips Medical Systems, 
Bothell, WA, USA), (2) HDI 5000 (Philips Medical Systems, 
Bothell, WA, USA), (3) LOGIQ9 (GE Healthcare, Milwaukee, 
WI, USA), (4) Aplio SSA-770A (Toshiba Medical Systems, 
Tokyo, Japan), and (5) EUB-7500 (Hitachi Medical Corporation, 
Tokyo, Japan). A 5–12-MHz or an 8–15-MHz linear-array 
transducer was used. Faculty radiologists specializing in head-
and-neck imaging or supervised board-certified radiologist 
who were participating in head-and-neck radiology fellowship 
training performed all US examinations. Postoperative US 
follow-up in MTC patients was commonly performed at 0.5-, 
1-, or 2-year intervals at each institution. The following features 
were investigated via US examination: suspicious thyroid nod-
ules in the remnant thyroid gland, masses in the postoperative 
thyroid bed and perithyroidal neck area, and suspicious lymph 
nodes or masses in the neck. In all patients, the interval (i.e., 
period between the initial surgery and postoperative follow-up 
US examination) and session number of postoperative follow-
up US were investigated. In the tumor recurrence/persistence 
group, the interval and session number of postoperative neck 
US where tumor recurrence/persistence was first detected were 
recorded.
Thyroid surgery and histopathology
Thyroid surgery was performed by board-certified surgeons of the 
affiliated hospitals. The extent of thyroid surgery was determined 
by multiple factors, including patient age, family history, tumor 
size, extrathyroidal tumor extension, multifocality, bilaterality, 
nodal metastasis, and distant metastasis. In the histopathological 
analysis, the intraglandular location of the MTC, perithyroidal 
tumor invasion within or beyond surgical margins, nodal metas-
tasis, and the presence of satellite MTC were recorded.
TaBle 1 | Demographics and characteristics in the 86 patients.
items
Age (mean ± SD, years) 53.1 ± 11.8 (range, 7–76)
Sex Female: male = 53 (61.6): 
33 (38.4)
Type of thyroid surgery
Total thyroidectomy 78 (90.7)
Hemithyroidectomy 7 (8.1)
Subtotal thyroidectomy 1 (1.2)
Size of primary MTC (mean ± SD, mm) 16.9 ± 13.7 (range, 3–88.6)





















Satellite MTC in the ipsilateral lobe 6 (7.0)
Satellite MTC in the contralateral lobe 1 (1.2)
Satellite MTC in both lobes 9 (10.5)
interval of the last follow-up Us (mean ± sD, 
months)
78.6 ± 24.9 (range, 23–141)
session number of the last follow-up Us 7.0 ± 3.3 (range, 1–18)
Data presented in parentheses are percentage of each item.
MTC, medullary thyroid carcinoma.
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classification of Tumor recurrence/
Persistence and non-recurrence
Nine board-certified radiologists from each of the affiliated 
hospitals retrospectively reviewed the postoperative follow-
up US, clinical, and histopathological results of the patients 
included in the study. The size, location, multiplicity, and TNM 
stage of tumors were investigated on the basis of US images and 
histopathological results. TNM stage was based on the guidelines 
of the American Joint Committee on Cancer (17). The sites of 
recurrence/persistence were classified as nodal, non-nodal, or 
unknown. Non-nodal recurrence/persistence was defined as the 
presence of an MTC in the remnant thyroid gland, postopera-
tive thyroid bed, or perithyroidal neck area during the follow-
up period after surgery as determined via histopathological 
examinations. Nodal recurrence/persistence was defined as the 
presence of a metastatic lymph node from MTC in the neck 
area during the follow-up period after surgery. US features of 
metastatic lymph nodes and local recurrent masses in the opera-
tive bed were characterized in accordance with previous reports 
(18, 19). In patients with tumor recurrence/persistence, the loca-
tion, diagnostic method, and management of tumor recurrence/
persistence were reviewed. An interval and session number of 
postoperative follow-up US were also recorded.
Serum calcitonin levels at the time of initial preoperative labo-
ratory investigations and final serologic tests were investigated. 
In the patients with tumor recurrence/persistence, the serum 
calcitonin level at the time of diagnosis of recurrence/persistence 
was defined as the final serum calcitonin value. Serum calcitonin 
levels were measured using immunoradiometric assays in eight 
affiliated hospitals, and chemiluminescence immunoassays in 
one hospital. The cutoffs for calcitonin levels were 0–10 pg/mL 
in seven of the hospitals using immunoradiometric assays, 0–14 
pg/mL in the remaining one hospital using immunoradiometric 
assays, and 0–8.4 pg/mL (male) or 0–5.0 pg/mL (female) in the 
one hospital using chemiluminescent immunoassays. In previ-
ous reports, a normal basal calcitonin level of <10 pg/mL has 
been used to exclude remnant MTC, and ≥10 pg/mL of serum 
calcitonin has been deemed indicative of recurrence/persistence 
(20, 21).
Based on the literature, postoperative disease status within 
6 months of surgery and at the last follow-up were classified as 
follows: (1) no tumor recurrence/persistence (biochemical remis-
sion as defined by a serum calcitonin level of <10 pg/mL and no 
structural disease evident via neck US or other available imaging 
modalities during postoperative follow-up), (2) only biochemical 
recurrence/persistence (serum calcitonin level of ≥10 pg/mL with 
no evidence of structural disease during postoperative follow-up), 
and (3) structural recurrence/persistence (with identification of 
structural recurrence/persistence on neck US or other available 
imaging modalities during postoperative follow-up) (20–22).
statistical analysis
All statistical analyses were performed using SPSS for Windows 
(version 21.0, SPSS, Chicago, IL, USA). Categorical variables 
were compared using the chi-square test or Fisher’s exact test, and 
continuous variables (age, tumor size, and serum calcitonin level) 
were compared using Student’s t-test. A p <0.05 was considered 
to indicate statistical significance. The prevalence of MTC recur-
rence/persistence was calculated, and the interval and session 
number of postoperative follow-up US were compared between 
the recurrence/persistence and non-recurrence groups. Also, we 
assessed correlations between tumor recurrence/persistence and 
variable clinicopathological factors, to predict prognosis.
resUlTs
Of the 86 patients, the mean size of the primary MTC was 
16.9 ± 13.7 mm (range 3.0–88.6 mm). The locations of the pri-
mary MTC included the right lobe (n = 59), the left lobe (n = 26), 
and the isthmus (n = 1). Thyroid surgery was performed in all 
86 patients, and the TNM stages based on histopathology of 
the surgical specimens are shown in Table 1. More than 50% of 
patients were diagnosed with intraglandular MTC. There were no 
cases of tumor invasion into the adjacent tracheal or esophageal 
wall. Nodal metastases in the lateral neck were demonstrated in 
FigUre 2 | A 54-year-old man with nodal recurrence/persistence of 
medullary thyroid carcinoma (MTC). Preoperative longitudinal gray-scale 
sonogram shows an MTC (arrows, 9.3 mm at its largest diameter) in the left 
thyroid lobe (a) and multiple metastatic lymph nodes (arrows) in the left lateral 
neck (B). On histopathological examination after total thyroidectomy with 
lateral neck dissection, there was perithyroidal tumor invasion (T3) and nodal 
metastasis in the left neck (N1b). The patient showed biochemical remission 
after thyroid surgery, and the first follow-up ultrasonography (US) at 12 months 
after thyroid surgery showed normal lymph nodes (arrows) in the left level-III 
neck (c). On the second follow-up US at 25 months after thyroid surgery, a 
transverse gray-scale sonogram (D) shows a suspicious LN (arrows, 19.9 mm 
at its largest diameter) in the left level-III neck. After US-guided fine-needle 
aspiration for this node, cytology revealed nodal metastasis of MTC, and this 
lesion was confirmed after the second-look surgery.
FigUre 1 | A 51-year-old man with non-nodal recurrence/persistence of 
medullary thyroid carcinoma (MTC). Preoperative longitudinal gray-scale 
sonograms show a primary MTC (arrows, 25.0 mm at its largest diameter) in 
the right thyroid lobe (a), and a metastatic lymph node (arrows) in the right 
lateral neck (B). On histopathological examination after total thyroidectomy 
with lateral neck dissection, there was perithyroidal tumor invasion (T3) and 
nodal metastasis in the right neck (N1b). The patient exhibited biochemical 
remission after thyroid surgery, and there was no focal lesion in the 
postoperative thyroid beds and necks on 6, 12, 18, or 24-month follow-up 
ultrasonography (US) after thyroid surgery. In the fifth follow-up US at 
30 months after thyroid surgery, transverse (c) and longitudinal (D) 
gray-scale sonograms showed an oval hypoechoic nodule (arrows, 8.0 mm 
at its largest diameter) in the right postoperative thyroid bed. After US-guided 
fine-needle aspiration for this lesion, cytology revealed suspicious MTC, and 
this lesion was confirmed as non-nodal recurrence/persistence of MTC after 
the second-look surgery.
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25 patients (29.1%). Distant metastasis was only noted in one 
patient (1.2%). The interval between thyroid surgery and the last 
follow-up US was 60 or more months in 74 patients (86.0%) and 
90 or more months in 22 patients (25.6%).
Of the 86 patients, 64 (74.4%) exhibited no tumor recurrence/
persistence during the follow-up period. Of the 22 (25.6%) 
remaining patients, 11 (50%) showed biochemical recurrence/
persistence with no structural recurrence/persistence and 11 
(50%) showed structurally identified recurrence/persistence 
(Figures 1 and 2).
Of the 11 patients with structural recurrence/persistence, 
tumor recurrence/persistence was initially detected by follow-
up US in eight, serum calcitonin analysis in two, and positron 
emission tomography-computed tomography (18F-labeled flude-
oxyglucose) in one. All patients with structural recurrence/
persistence showed suspicious US features on follow-up US. 
Final diagnosis of tumor recurrence/persistence was performed 
by US-guided fine-needle aspiration in six patients, and second-
look surgery in five. Nine of the 11 patients with structural recur-
rence/persistence exhibited nodal recurrence/persistence, and 
two exhibited non-nodal recurrence/persistence. In this group, 
the mean period and session number of the follow-up US in 
which tumor recurrence/persistence was initially detected were 
41.3 ± 39.3 months (range 6–128 months) and 2.6 ± 2.3 (range 
1–8), respectively. Six of the 11 patients were diagnosed with 
tumor recurrence/persistence within 3 years of the initial surgery 
(6, 12, 21, 22, 25, and 33  months), and the remaining 4 were 
diagnosed at 50 (fifth), 62 (fourth session), 92 (seventh session), 
98 (seventeenth session), and 128 (eighth session) months after 
the initial surgery. The structural recurrence/persistence group 
showed a mean serum calcitonin level of 662.5 ± 1634.7 pg/mL 
(range 19.2–5545.0 pg/mL).
Among the patient demographics variables and general char-
acteristics of the primary tumor, tumor recurrence/persistence 
was significantly correlated with TNM stage and multiplicity/
bilaterality of the tumor (Table  2). The primary MTCs in the 
recurrent/persistent group exhibited higher T and N stages than 
those of the non-recurrent group (both p < 0.001). Preoperative 
distant metastasis was only reported in 1 patient who showed 
tumor recurrence/persistence during the follow-up period. 
In the non-recurrence group, 56 patients (87.5%) exhibited 
solitary MTC in surgical specimen. However, there was a high 
prevalence of multiple and/or bilateral MTCs in the recurrence/
persistence group compared with the non-recurrence group 
(p = 0.013). Factors such as age, sex of the patient, and the location 
and method of surgical excision of the tumor did not differ signifi-
cantly between the recurrence/persistence and non-recurrence 
groups. There were statistically significant differences in mean 
interval and session number of postoperative follow-up US 
between the non-recurrence group (74.7 months and 6.4, respec-
tively) and the tumor recurrence/persistence group (89.9 months 
and 8.7, respectively) (p = 0.013 and 0.005, respectively).
In preoperative serologic tests, the serum calcitonin level was 
significantly higher in the tumor recurrence/persistence group 
(mean 4202.9 ± 15380.3 pg/mL, range 52.3–67633.0 pg/mL) than 
in the non-recurrence group (mean 277.4 ± 775.9 pg/mL, range 
1.5–5790.0 pg/mL) (p = 0.042). In the last serologic test, there 
was a significant difference in the serum calcitonin levels of the 








Age (mean ± SD, years) 52.3 ± 12.6 53.5 ± 12.0 0.708
Sex 0.999
Female 39 (60.9) 14 (63.6)
Male 25 (39.1) 8 (36.4)
Type of thyroid surgery 0.755
Total thyroidectomy 57 (89.1) 21 (95.5)
Hemithyroidectomy 6 (9.4) 1 (4.5)
Subtotal thyroidectomy 1 (1.6) 0 (0)
size of primary MTc (mm) 15.9 ± 14.4 19.7 ± 11.1 0.263
location of primary MTc 0.999
Right 44 (68.8) 15 (68.2)
Left 19 (29.7) 7 (31.8)
Isthmus 1 (1.6) 0 (0)
T stage <0.001
T1a 20 (31.3) 2 (9.1)
T1b 25 (39.1) 4 (18.2)
T2 8 (12.5) 2 (9.1)
T3 11 (17.2) 14 (63.6)
T4a 0 (0) 0 (0)
n stage  <0.001
Nx (unknown) 3 (4.7) 0 (0)
N0 36 (56.3) 2 (9.1)
N1a 16 (25) 4 (18.2)
N1b 9 (14.1) 16 (72.7)
M stage  <0.001
Mx (unknown) 6 (9.4) 9 (40.9)
M0 58 (90.6) 12 (54.5)
M1 0 (0) 1 (4.5)
Multiplicity/bilaterality 0.013
Solitary 56 (87.5) 14 (63.6)
Satellite MTC in the ipsilateral lobe 2 (3.1) 4 (18.2)
Satellite MTC in the contralateral lobe 0 (0) 1 (4.5)
Satellite MTC in both lobes 6 (9.4) 3 (13.6)
interval of the last follow-up Us 
(mean ± sD, months)
74.7 ± 24.2 89.9 ± 23.8 0.013
session number of the last follow-
up Us
6.4 ± 2.8 8.7 ± 4.0 0.005
Data presented in parentheses are percentage of each item.
MTC, medullary thyroid carcinoma; US, ultrasonography.
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two groups (p = 0.002). The tumor recurrence/persistence group 
showed significantly higher levels of serum calcitonin (mean 
563.2 ± 1362.4 pg/mL, range 6.1–5545.0 pg/mL) than the non-
recurrence group (mean 3.2 ± 2.2 pg/mL, range 1–9.3 pg/mL).
DiscUssiOn
Many studies have investigated various prognostic factors in MTC 
patients (7–9, 23). Distant metastasis (known to be the main cause 
of mortality), advanced age, primary tumor stage, and nodal stage 
have been proposed as prognostic factors (7–9). As in these prior 
studies, TNM stage and multiplicity/bilaterality of the primary 
tumor were significantly correlated with tumor recurrence/
persistence in our study. However, age and sex of the patient were 
not correlated with tumor recurrence/persistence in the present 
study, although they have been reported as prognostic factors in 
previous studies (8, 9, 23). The reason for this difference is unclear. 
However, the small sample size of MTC patients and tumor recur-
rence/persistence cases may be associated with discrepancy.
In the present study, the serum calcitonin levels detected in 
the preoperative and final serologic tests were compared between 
tumor recurrence/persistence and non-recurrence groups. Higher 
serum calcitonin levels are widely known to be predictive of MTC. 
Cohen et al. demonstrated that tumor size was significantly cor-
related with preoperative serum calcitonin level (24). Also, they 
reported that a preoperative serum calcitonin level <50 pg/mL 
was predictive of postoperative calcitonin normalization. Several 
studies have reported that postoperative calcitonin level is of 
predictive value with regard to disease progression and persis-
tence (21, 25, 26). In our study, serum calcitonin levels in both 
preoperative and postoperative serologic tests were significantly 
correlated with tumor recurrence/persistence, as has been 
reported in previous studies (21, 25, 26).
In MTC patients, rates of structural recurrence ranging from <1 
to 10.6% have been reported (21, 22). The rate of structural recur-
rence/persistence was 12.8% (11/86) in our study. Most of these 
(54.5%, 6/11) were detected within 3 years after the initial thyroid 
surgery. However, the remaining tumor recurrence/persistence 
cases were detected on follow-up US during 4–11  years after 
thyroid surgery. Of the 11 patients with structural recurrence/
persistence, 8 had the initial detection of recurrence/persistence 
by follow-up US. Based on our study results, we recommend the 
following method of follow-up US for detecting tumor recur-
rence/persistence in MTC patients: (1) the follow-up US with 
annual interval is performed within 3 years after thyroid surgery 
and (2) the follow-up US with biennial interval is performed dur-
ing 4–10 years after thyroid surgery. However, this method may 
be changeable depending on risk factors of tumor recurrence/
persistence. For clarity, a large-scale study may be required.
In the present study, there were significant differences in mean 
interval and mean session number of follow-up US between the 
non-recurrence group and the tumor recurrence/persistence group. 
Namely, tumor recurrence/persistence group had longer periods of 
follow-up US, and more frequent sessions than the non-recurrence 
group. The reason for this may be associated with that recurrent/
persistent patients had been diagnosed at a point in time during their 
follow-up, consequently they underwent more frequent follow-up 
US over a longer period of time than non-recurrence patients.
This study had several limitations. First, the sample size of the 
study was small. This can compromise the statistical interpretation 
of results. Second, retrospective analyses of medical records and 
US images were performed. This may have resulted in unavoid-
able selection bias. Third, we did not distinguish tumor recur-
rence from persistence. Finally, there were differences between 
the affiliated hospitals with regard to postoperative follow-up US 
protocols and serum calcitonin measurement. To overcome these 
limitations, a prospective study with a large patient population 
must be considered in the near future.
In conclusion, the tumor recurrence/persistence rate of MTC 
in the neck was 25.6% (22/86), the proportion of structural 
recurrence/persistence was 50% (11/22), and tumor recurrence/
persistence was associated with advanced TNM stage and mul-
tiplicity/bilaterality. In the majority of patients with structural 
recurrence/persistence in the neck, tumor recurrence/persistence 
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was detected during early follow-up US, within 3 years from the 
initial thyroid surgery. Thus, for detecting MTC recurrence/
persistence in the neck, annual US surveillance may be sufficient 
within the first 3 years after thyroid surgery, but depending on the 
presence of relevant risk factors, annual or biannual US surveil-
lance may be recommendable for 4–10 years after thyroid surgery.
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